BRIEF-EMA’S Emergency Task Force Cautions Higher Risk Of Local Reactions After Intradermal Injections

BRIEF-EMA’S Emergency Task Force Cautions Higher Risk Of Local Reactions After Intradermal Injections

European Medicines Agency: * EMA: EMA’S EMERGENCY TASK FORCE ADVISES ON INTRADERMAL USE OF IMVANEX / JYNNEOS AGAINST MONKEYPOX : 19/08/2022

* EMA: ETF CAUTIONED HIGHER RISK OF LOCAL REACTIONS (E.G. LONGER-LASTING REDNESS, THICKENING OR DISCOLORATION OF SKIN) AFTER INTRADERMAL INJECTIONS * EMA: NATIONAL AUTHORITIES MAY DECIDE TO USE IMVANEX TEMPORARILY AS INTRADERMAL INJECTION AT LOWER DOSE TO PROTECT AT-RISK INDIVIDUALS

Give Feedback

Use this form for editorial or site feedback. We usually reply within 2 to 3 working days.

By submitting, you agree that we may use your email address to respond.